Digital inhalers can detect significant changes in physiologic and inhaler use metrics in the 14 days before COPD exacerbations.

Teva Pharmaceuticals failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ProAir HFA inhaler from the U.S. Food and Drug Administration ...

Key takeaways: The ProAir Digihaler captured peak inspiratory flow, inhalation volume, inhalation duration, time to peak inhalation and inhaler use. Three metrics changed significantly before an ...

Hoyte: Results from the study showed adults and children aged 13 years and older with uncontrolled asthma using the ProAir Digihaler and its integrated system had an 85.3% probability of higher ...

During the 14 days preceding acute exacerbations of COPD, there were statistically significant reductions in mean inhalation volume (1.45 versus 1.08 L), inhalation duration (1,876 versus 1,492.1 ...

Late last week, the FTC filed an amicus brief in New Jersey federal court, arguing that Teva “improperly listed” patents on its asthma inhaler ProAir HFA in the Orange Book. Teva used those ...

Teva is discontinuing its Digihaler ® products, ProAir ® Digihaler ® (albuterol sulfate), AirDuo ® Digihaler ® (fluticasone propionate and salmeterol inhalation powder) and ArmonAir ...